MARKET

BLCM

BLCM

Bellicum Pharms
NASDAQ

Real-time Quotes | Nasdaq Last Sale

7.37
+0.10
+1.38%
After Hours: 7.20 -0.17 -2.31% 16:17 05/27 EDT
OPEN
7.27
PREV CLOSE
7.27
HIGH
7.43
LOW
6.80
VOLUME
70.71K
TURNOVER
--
52 WEEK HIGH
27.90
52 WEEK LOW
3.320
MARKET CAP
37.22M
P/E (TTM)
-0.4246
1D
5D
1M
3M
1Y
5Y

Analyst Rating

Based on 3 analysts

Strong Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target

The average BLCM stock price target is 17.33 with a high estimate of 25.00 and a low estimate of 9.00.

EPS

BLCM News

More
Bellicum Announces Publication of Data for GoCAR-NK™ Cell Program
HOUSTON, May 27, 2020 -- Bellicum Pharmaceuticals, Inc. (NASDAQ:BLCM), a leader in developing novel, controllable cellular immunotherapies for cancers, today announced the.
GlobeNewswire · 9h ago
Bellicum to Participate in Two Upcoming Virtual Investor Conferences
GlobeNewswire · 16h ago
All You Need to Know About Bellicum Pharmaceuticals (BLCM) Rating Upgrade to Strong Buy
Bellicum Pharmaceuticals (BLCM) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank 1 (Strong Buy).
Zacks · 5d ago
96 Biggest Movers From Friday
Gainers Fuel Tech, Inc (NASDAQ: FTEK) shares climbed 93.6% to close at $0.91 on Friday after the company reported FUEL CHEM® demonstration orders from two new industrial power customers.
Benzinga · 05/11 09:14
AAOI, HEAR, RIOT and BLCM among midday movers
Seeking Alpha - Article · 05/08 16:44
Bellicum Pharmaceuticals Q1 EPS $1.090 May Not Compare To $(0.550) YoY
Bellicum Pharmaceuticals (NASDAQ:BLCM) reported quarterly earnings of $1.090 per share. This is a 298.18 percent increase over losses of $(0.550) per share from the same period last year.
Benzinga · 05/07 20:45
Bellicum Reports First Quarter 2020 Financial Results and Provides Operational Update  
Bellicum’s three GoCAR™ programs remain on track Completed $15 million sale of manufacturing, office and laboratory facility to MD Anderson and entered into supply agreement.
GlobeNewswire · 05/07 20:05
The Bellicum Pharmaceuticals (NASDAQ:BLCM) Share Price Is Down 98% So Some Shareholders Are Very Salty
Simply Wall St. · 05/06 15:29

Industry

Biotechnology & Medical Research
+0.53%
Pharmaceuticals & Medical Research
+0.23%

Hot Stocks

Symbol
Price
%Change

About BLCM

Bellicum Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on discovering and developing cellular immunotherapies for various forms of cancer, including hematological cancers and solid tumors, as well as orphan inherited blood disorders. The Company uses its chemical induction of dimerization (CID) technology platform to engineer and then control components of the immune system. The Company is developing next-generation product candidates in the areas of cellular immunotherapy, including hematopoietic stem cell transplantation (HSCT), chimeric antigen receptors (CAR) T cells therapy and T-cell receptor (TCR) cell therapies. The Company's product candidates include BPX-501, BPX-601 and BPX-701. The Company's CID-based technologies include CaspaCIDe and GoCAR-T. It is evaluating BPX-501 in various Phase I/II clinical trials in adults and pediatric patients with leukemias, lymphomas and genetic blood diseases in the United States and Europe.
More

Webull offers kinds of Bellicum Pharmaceuticals Inc stock information, including NASDAQ:BLCM real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, BLCM stock news, and many more online research tools to help you make informed decisions.